Solasia Pharma K.K. (4597.T) JPX

24.00

+0(+0.00%)

Updated at June 03 03:30PM

Currency In JPY

Solasia Pharma K.K.

Address

Sumitomo Fudosan Shiba-Koen Tower

Tokyo, 105-0011

Japan

Phone

81 3 5843 8045

Website

https://www.solasia.co.jp

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

First IPO Date

March 27, 2017

Key Executives

Name	Title	Pay	Year Born
Yoshihiro Arai	President, Chief Executive Officer & Representative Director	0	1960
Yasuaki Manabe	Head of Marketing Division	0	N/A
Toshio Miyashita	Chief Financial Officer, Head of Management Headquarters & Director	0	1967
Yasumitsu Shimada	Accounting Manager	0	N/A
Kozo Yao	Head of Business Development	0	N/A
Wataru Kobayashi	Head of Reliability Assurance Division	0	N/A
Fumiko Nagahama	Head of Product Development Division	0	N/A
Hikaru Osawa	Head of Production Management Division	0	N/A

Description

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.